Trial Profile

A clinical study of BE-102 for treatment of hypophosphatasia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BE-102 (Primary)
Indications Hypophosphatasia
Focus Adverse reactions; First in man

Most Recent Events

17 May 2025 According to a Be Biopharma media release, company anticipates submission of IND for a first-in-human clinical trial for people with HPP.
12 Feb 2025 New trial record
06 Feb 2025 According to a Be Biopharma media release, company expects to initiate clinical development for BE-102 for the treatment of hypophosphatasia during 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com